CCAL
NBIX icon

City Center Advisors LLC’s Neurocrine Biosciences NBIX Stock Holding History

City Center Advisors LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$285K Sell
2,010
-235
-10% -$37.8K 0.22% 133
2026
Q2 		$378K Buy
+2,245
New +$333K 0.31% 103
2025
Q3 		– Sell
-2,006
Closed -$252K – 179
2025
Q2 		$252K Buy
+2,006
New +$230K 0.27% 121

Other funds holding NBIX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
PCS
Private Client Services Louisville, Kentucky $372M AUM 17.65% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

City Center Advisors LLC's NBIX Position: Q3 2026 in Review

City Center Advisors LLC reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q3 2026, selling an estimated $37.8K and leaving 2,010 shares worth $285K. The position accounts for 0.22% of the portfolio, ranked #133.

City Center Advisors LLC first reported a position in NBIX in Q2 2025 and has held it in 3 quarters since. The position peaked at $378K in Q2 2026. 21 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • City Center Advisors LLC held 2,010 shares of Neurocrine Biosciences worth $285K as of Q3 2026.
  • City Center Advisors LLC sold 235 Neurocrine Biosciences shares in Q3 2026, an estimated $37.8K.
  • Neurocrine Biosciences made up 0.22% of City Center Advisors LLC's portfolio in Q3 2026, its #133 holding.
  • City Center Advisors LLC first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 3 quarters since.
  • City Center Advisors LLC's Neurocrine Biosciences position peaked at $378K in Q2 2026.
  • 21 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on City Center Advisors LLC's 13F filing for Q3 2026, filed 8 Oct 2026.